Australia’s Cell Therapies partners with Teijin to expand access to advanced cell and gene therapies in Japan and APAC region
October 1, 2025 | Wednesday | News
To combine Cell Therapies’ long-standing expertise with Teijin’s strong manufacturing capabilities
Australia-based Cell Therapies and Japan’s Teijin Limited have signed a Memorandum of Understanding (MoU) to strengthen regional infrastructure for cell and gene therapies (CGT), leveraging advanced GMP capabilities and cross-border collaboration to accelerate development and improve patient access across Japan and the wider Asia Pacific region.
This partnership will combine Cell Therapies’ long-standing expertise as Australia’s leading CGT CDMO with Teijin’s strong manufacturing capabilities in CGT and regenerative medicine via their group companies Teijin Regenet Co. and Japan Tissue Engineering Co.（J-TEC）in Japan.
The collaboration aims to streamline access to regional markets by enabling cross-border clinical trial and commercial supply, knowledge exchange, and regulatory alignment to support innovative CGT programs.
Through this collaboration, the companies intend to:
Expand regional GMP manufacturing capacity for cell and gene therapies (CGT)
Enable efficient technology transfer and multi-site delivery across APAC
Facilitate clinical trial and market access for advanced therapies in Japan and Australia
Build long-term infrastructure and capability through joint training and workforce development initiatives
AloJapan.com